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Introduction
The intellectual disability is found in approxi-
mately 2–3% of the population in a mild-to-moder-
ate form and 0.5-1% a moderate-to-severe form(1).
The etiology can be different (unknown and
environmental causes(2), chromosomal anomalies(3-6),
genetic mutations(7), prenatally, perinatally, or post-
natally causes etc.) and a careful anamnesis is nec-
essary for a correct diagnosis.
When in a single family are more males with
intellectual disability in pedigree of three genera-
tions, we suppose that it is caused by X-linked
pathology, even if the clinical diagnosis of intellec-
tual disability X-linked (XLID) is usually a diagno-
sis of exclusion of other causes of developmental
delay in male.
Intellectual disability is more common in the
male rather than in the female population, due to
mutations on the X chromosome(8-10). 
XLID is generally divided into syndromic
forms, in which intellectual disability is only one of
a large set of symptoms, and non-syndromic forms,
in which intellectual disability is the only manifes-
tation of the pathology(1). 
The syndromic forms are prevalent, and about
one half of XLID patients also manifest autism
and/or seizures. To date, more than 150 XLID syn-
dromes have been characterized and 102 XLID
genes have been identified, accounting for 81 of
these syndromes(8).
The XLID genes encode for proteins that are
highly expressed in the brain, especially in the hip-
pocampus, a region that plays a key role in learning
and memory.
We report the data for three X-linked syn-
dromes with intellectual disability.
Fragile X syndrome
Fragile X syndrome is a rare genetic disease
associated with typical dysmorphism and mild to
severe intellectual deficit that may be associated
with behavioral disorders.
The clinical phenotype is variable. Prevalence
is estimated at approximately 1/2,500 (prevalence
of the full mutation allele) to 1/4,000 (prevalence of
symptomatic cases)(11) for both genders.
The majority of males with Fragile X syn-
drome reveal significant intellectual disability (for-
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merly referred to as “mental retardation”).
Disabilities in Fragile X syndrome include a range
from moderate learning disabilities to more severe
intellectual ones. In males, the disease occurs dur-
ing childhood with delayed developmental mile-
stones (motor and/or language delay)(12,13). In males
and in 50% of females, intellectual disorders asso-
ciated with behavioral problems and/or dysmorphic
features appear. Behavioral characteristics can
include attention deficit / hyperactivity disorder
(ADD/ADHD), autism and autistic behaviors,
social anxiety, hand-biting and/or flapping, poor
eye contact, sensory disorders and increased risk
for aggression(14-16). Mood disorders, anxiety and
aggressive behavior can be present(17). In females,
intellectual and behavioral disorders are mild (emo-
tional and learning problems). Physical features
may include large ears, long face, soft skin and
large testicles (called “macroorchidism”) in post-
pubertal males. Connective tissue problems may
include ear infections(18), flat feet, high-arched
palate, double-jointed fingers and hyper-flexible
joints. Fragile X is caused by a “full” mutation in
the fragile X mental retardation 1 (FMR1) gene,
which creates a protein called “fragile X mental
retardation protein” (FMRP). Nearly all cases of
fragile X syndrome are caused by a mutation in
which a DNA segment, known as the CGG triplet
repeat, is expanded within the FMR1 gene.
Normally, this DNA segment is repeated from 5 to
about 40 times. In people with fragile X syndrome,
however, the CGG segment is repeated more than
200 times. The abnormally expanded CGG segment
turns off (silences) the FMR1gene, which prevents
the gene from producing FMRP. Loss or a shortage
(deficiency) of this protein disrupts nervous system
functions and leads to the signs and symptoms of
fragile X syndrome(19). Premutations are associated
with phenotypes distinct from Fragile X syndrome
including a risk of premature ovarian insufficiency
in women, and the fragile X-associated tremor/atax-
ia syndrome. In some rare cases, Fragile X syn-
drome was shown to result from intragenic FMR1
point mutations rather than expansion of a CGG
repeat. One function of the FMRP protein in the
brain is to put the brakes on another protein in the
brain, called “metabotropic glutamate receptor 5”
(MGluR5). MGluR5 tells theneuronsto growden-
drites, which are long, narrow parts that allow them
to attach to other neurons. When the dendrites are
the right size and shape, FMRP makes MGluR5 tell
the neurons to stop. When FMRP is missing, the
dendrites grow wild and uncontrolled. Fragile X
syndrome is an X-linked dominant disorder with
reduced penetrance in females. Genetic counseling
should be offered to families of an affected individ-
ual in order to explain the mode of inheritance of
the mutations (there is a 50% recurrence risk in pre-
mutated females). Prenatal diagnosis is possible on
samples of chorionic villi or amniotic fluid. Most
patients with fragile X syndrome generally have a
normal life span.
New targeted treatments for Fragile X syn-
drome (mGluR5 antagonists, GABA A and B ago-
nists, minocycline) are now being studied.
Alpha thalassemia - X-linked intellectual deficit
syndrome
X-linked alpha thalassemia mental retardation
(ATR-X) syndrome is a rare, inherited condition
characterized by severe intellectual disability, char-
acteristic facial features, genital abnormalities and
alpha thalassemia(20-22).
Female carriers are usually physically and
intellectually normal. 
The phenotype is usually characterized by dis-
tinctive craniofacial features, genital anomalies,
severe developmental delays, hypotonia, intellectu-
al disability, and mild-to-moderate anemia sec-
ondary to alpha-thalassemia associated with spas-
ticity or seizures, and growth retardation with mid-
face hypoplasia and skeletal abnormalities and gas-
tro-esophageal reflux that may cause death(23).
Craniofacial abnormalities include microcephaly,
telecanthus or ocular hypertelorism, small nose,
tented upper lip, and prominent or everted lower lip
with coarsening of the facial features over time.
This syndrome is X-linked recessive and
results from mutations in the ATRX gene, which
encodes an ATP-dependent chromatin-remodeler.
This disease results in severe disability and short-
ened lifespan. The best way to diagnose this condi-
tion is to identify a gene mutation in the affected
individual through molecular genetic testing of the
ATRX gene. Genetic counseling can be offered to
families. 
Rett syndrome
Rett syndrome is a genetic disorder that affects
approximately 1 in 12,000 females (it is rarelyseen
in males). Rett syndrome primarily affects females,
making it one of the most common genetic causes
of severe intellectual disability in females. 
It causes severe physical and mental disability
that begins in early childhood.
The changes typically appear in the first 6-18
months of the infant’s life. These include:
• a general slowness in development; 
• floppiness; 
• difficulty in feeding; 
• abnormal hand movements (such as repeat-
edly making wringing, clapping or washing
motions with the hands); 
• less interest in social contact and eye con-
tact;  
• not very interested in toys;  
• walking awkwardly and poor co-ordination
of trunk and limbs. 
The “rapid destructive stage”, usually begins
between the ages of one and four and may last for
weeks or months.The children will gradually or
suddenly start to develop severe problems with
communication, language, learning, co-ordination
and other brain functions(24-26). 
Despite the identification of mutations in the
X-linked gene methyl CpG-binding protein 2
(MECP2) in the majority of Rett syndrome patients,
the etiology remains unclear. More recently muta-
tions in two other genes, cyclin-dependent kinase
like 5 (CDKL5) and Netrin G1, have been identi-
fied in patients with a clinical phenotype that
strongly overlaps with Rett syndrome. Life
expectancies are not well studied, although survival
at least until the mid-20s is likely. The average life
expectancy of a girl with Rett syndrome may be
mid-40s. Death is often related to seizure, aspira-
tion pneumonia and malnutrition(27,28).
Conclusion
Management of XLID is symptom-based and
requires a multidisciplinary approach, which should
be combined with speech therapy, sensory integra-
tion occupational therapy, individualized education-
al plans, and behavioral interventions. Genetic
counseling and prenatal diagnosis can be offered to
families. 
diabetic patients independently of HT and
heart failure. Prospective studies with a larger
cohort are now needed to observe the effects of CT-
1 treatment in a diabetic population.
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